Epithelioid GBMs show a high percentage of BRAF V600E mutation

American Journal of Surgical Pathology

Volumn 37, Issue 5, 2013, Pages 685-698

  Kleinschmidt Demasters, Bette Kay ^a   Aisner, Dara L ^a   Birks, Diane K ^a,b   Foreman, Nicholas K ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

BRAF; epithelioid GBM; ganglioglioma; giant cell GBM; IDH 1; pleomorphic xanthoastrocytoma

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TUMOR; CHILD; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICRODISSECTION; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICRODISSECTION; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84876680857     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31827f9c5e     Document Type: Article

References (41)

1. Dougherty MJ, Santi M, Brose MS, et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol. 2010;12:621-630.
2. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011;6:e17948.
3. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121: 397-405.
4. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597-602
5. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11:341-347.
6. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-254.
7. Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer. 1979;44:1839-1852.
8. Kepes JJ, Rubinstein LJ, Ansbacher L, et al. Histopathological features of recurrent pleomorphic xanthoastrocytomas: further corroboration of the glial nature of this neoplasm. A study of 3 cases. Acta Neuropathol. 1989;78:585-593.
9. Giannini C, Scheithauer BW, Burger PC, et al. Pleomorphic xanthoastrocytoma. Cancer. 1999;85:2033-2045.
10. Giannini C, Paulus W, Louis DN, et al. Pleomorphic xanthoas-trocytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. 3rd ed. Lyon: IARC; 2007:22-24.
11. MacKenzie JM. Pleomorphic xanthoastrocytoma in a 62-year-old male. Neuropathol Appl Neurobiol. 1987;13:481-487.
12. Marton E, Feletti A, Orvieto E, et al. Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature. J Neurol Sci. 2007;252:144-153.
13. Kros JM, Vecht CJ, Stefanko SZ. The pleomorphic xanthoastrocy-toma and its differential diagnosis: a study of five cases. Hum Pathol. 1991;22:1128-1135.
14. Chakrabarty A, Mitchell P, Bridges LR, et al. Malignant transformation in pleomorphic xanthoastrocytoma- A report of two cases. Br J Neurosurg. 1999;13:516-519.
15. Fu Y-J, Miyahara H, Uzuka T, et al. Intraventricular pleomorphic xanthoastrocytoma with anaplastic features. Neuropathol. 2010;30: 443-448.
16. Ng WH, Lim T, Yeo TT. Pleomorphic xanthoastrocytoma in elderly patients may portend a poor prognosis. J Clin Neurosci. 2008;15: 476-478.
17. Prayson RA, Morris HH 3rd. Anaplastic pleomorphic xanthoas-trocytoma. Arch Pathol Lab Med. 1998;122:1082-1086.
18. Hirose T, Ishizawa K, Sugiyama K, et al. Pleomorphic xanthoas-trocytoma: a comparative pathological study between conventional and anaplastic types. Histopathology. 2008;52:183-193.
19. Sugita Y, Shigemori M, Okamoto K, et al. Clinicopathological study of pleomorphic xanthoastrocytoma: correlation between histological features and prognosis. Pathol Int. 2000;50:703-708.
20. Tan T-C, Ho L-C, Yu C-P, et al. Pleomorphic xanthoastrocytoma: report of two cases and review of the prognostic factors. J Clin Neurosci. 2004;11:203-207.
21. Tekkok IH, Sav A. Anaplastic pleomorphic xanthoastrocytomas. Review of the literature with reference to malignancy potential. Pediatr Neurosurg. 2004;40:171-181.
22. Okazaki T, Kageji T, Matsuzaki K, et al. Primary anaplastic pleomorphic xanthoastrocytoma with widespread neuroaxis dissemination at diagnosis- A pediatric case report and review of the literature. J Neurooncol. 2009;94:431-437.
23. Vu TM, Liubinas SV, Gonzales M, et al. Malignant potential of pleomorphic xanthoastrocytoma. J Clin Neurosci. 2012;19:12-20.
24. Korshunov A, Golanov A. Pleomorphic xanthoastrocytomas: immunohistochemistry, grading and clinico-pathologic correlations. An analysis of 34 cases from a single Institute. J Neurooncol. 2001;52:63-72.
25. Macaulay RJ, Jay V, Hoffman HJ, et al. Increased mitotic activity as a negative prognostic indicator in pleomorphic xanthoastrocyto-ma. Case report. J Neurosurg. 1993;79:761-768.
26. Pahapill PA, Ramsay DA, Del Maestro RF. Pleomorphic xanthoas-trocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. Neurosurgery. 1996;38:822-829.
27. Kleihues P, Burger PC, Aldape KD, et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Albany, New York: WHO Publications Center; 2007:33-49.
28. Martinez-Diaz H, Kleinschmidt-DeMasters BK, Powell SZ, et al. Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin. Arch Pathol Lab Med. 2003;127:1187-1191.
29. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res. 1997;3:523-530.
30. Rosenblum MK, Erlandson RA, Budzilovich GN. The lipid-rich epithelioid glioblastoma. Am J Surg Pathol. 1991;15:925-934.
31. Fuller GN, Goodman JC, Vogel H, et al. Epithelioid glioblastoma: a distinct clinicopathologic entity. J Neuropathol Exp Neurol. 1998;57:501.
32. Akimoto J, Namatame H, Haraoka J, et al. Epithelioid glioblasto-ma: a case report. Brain Tumor Pathol. 2006;22:21-27.
33. Rodriguez FJ, Scheithauer BW, Giannini C, et al. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer. 2008;113:2779-2789.
34. Gasco J, Franklin B, Fuller GN, et al. Multifocal epithelioid glioblastoma mimicking cerebral metastasis: case report. Neuro-cirugia (Astur). 2009;20:550-554.
35. Kleinschmidt-DeMasters BK, Alassiri AH, Birks DK, et al. Epithelioid versus rhabdoid glioblastomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not Claudin 6. Am J Surg Pathol. 2010;34:341-354.
36. Tanaka S, Nakada M, Hayashi Y, et al. Epithelioid glioblastoma changed to typical glioblastoma: the methylation status of MGMT promoter and 5-ALA fluorescence. Brain Tumor Pathol. 2011;28:59-64.
37. Kaulich K, Blaschke B, Numann A, et al. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas. J Neuropathol Exp Neurol. 2002;61:1091-1099.
38. Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012;18: 3242-3249.
39. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
40. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.
41. Nicolaides TP, Li H, Solomon DA, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res. 2011;17: 7595-7604.